logo
  Join        Login             Stock Quote

4 Active Stocks on Traders' Radar Screens for 04/30/12: BMSN, BKS, GPRO, SEFE

Monday, April 30, 2012 10:03 AM


http://media.marketwire.com/attachments/201109/24448_FNM_logo.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=880599&ProfileId=051205&sourceType=1

CORAL SPRINGS, FL -- (Marketwire) -- 04/30/12 -- FinancialNewsMedia.com "stocks to watch" for today: Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), Barnes & Noble, Inc. (NYSE: BKS), Gen-Probe Incorporated (NASDAQ: GPRO), SEFE, Inc. (OTCBB: SEFE).

Breaking News Alert: Monday before the markets opened for trading, Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 In Institutional Funding. Southridge Partners is to provide the $20 million in funding for the rapid commercialization of stem cell therapies.

Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.

To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.

"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."

Read the entire BMSN press release announcing Bio-Matrix Scientific Group's new subsidiary, Regen BioPharma, Inc. along with their full disclosure here: http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=148

Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com.


Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.